メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
並べ替え順
Keyphrases
Colorectal Cancer
100%
Proteinuria
100%
Multicenter Cohort Study
100%
Bevacizumab Therapy
100%
Ramucirumab
100%
Treatment Group
33%
Bevacizumab
33%
Overall Survival
22%
Irinotecan
22%
Fluorouracil
22%
Folinic Acid
22%
Metastatic Colorectal Cancer (mCRC)
22%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
22%
Cumulative Incidence
11%
Comorbidity
11%
Subdistribution Hazard
11%
Later-line
11%
Fine-Gray Model
11%
Grade 23
11%
Medicine and Dentistry
Cohort Analysis
100%
Proteinuria
100%
Bevacizumab
100%
Colorectal Carcinoma
100%
Ramucirumab
100%
Treatment Group
30%
Overall Survival
20%
Vasculotropin
20%
Irinotecan
20%
Folinic Acid
20%
Fluorouracil
20%
Metastatic Colorectal Cancer
20%
Cumulative Incidence
10%
Comorbidity
10%
Pharmacology, Toxicology and Pharmaceutical Science
Proteinuria
100%
Cohort Study
100%
Bevacizumab
100%
Colorectal Carcinoma
100%
Ramucirumab
100%
Treatment Group
30%
Overall Survival
20%
Fluorouracil
20%
Vasculotropin
20%
Irinotecan
20%
Folinic Acid
20%
Metastatic Colorectal Cancer
20%
Comorbidity
10%
Neuroscience
Bevacizumab
100%
Ramucirumab
100%
Colorectal Carcinoma
100%
Vascular Endothelial Growth Factor
20%
Fluorouracil
20%
Folinic Acid
20%
Irinotecan
20%
Comorbidity
10%
Immunology and Microbiology
Bevacizumab
100%
Ramucirumab
100%
Colorectal Carcinoma
100%
Overall Survival
20%
Vasculotropin
20%
Irinotecan
20%
Comorbidity
10%